Group 1 - The core point of the article is that Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the registration of Linggui Zhugan Decoction Granules, which is expected to positively impact the company's performance [1][2]. - The drug is classified as a traditional Chinese medicine (Category 3.1) and is intended for the treatment of symptoms related to insufficient middle yang and phlegm-dampness [1][2]. - The company has invested approximately 12.7 million RMB in the research and development of this drug [2]. Group 2 - As of the announcement date, there are four approved drug registration numbers for Linggui Zhugan Decoction Granules, with the company being the fourth to receive approval [2]. - The market for cardiovascular disease medications, including traditional Chinese medicine, reached a total sales amount of 50.431 billion RMB in 2024, showing a year-on-year decline of 3.10% [2]. - The sales amount for Linggui Zhugan Decoction Granules in 2024 was reported to be 210,000 RMB, following its market entry in December 2022 [2].

证券简称：康恩贝 证券代码：600572 编号：2025-045 浙江康恩贝制药股份有限公司 关于苓桂术甘汤颗粒获得药品注册证书的公告 剂型：颗粒剂 规格：每袋装 10g（相当于饮片 55.2g） 注册分类：中药 3.1 类 上市许可持有人：浙江康恩贝制药股份有限公司 批准文号：国药准字 C20250010 证书编号：2025S02565 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称"公司""本公司"）收到国家药品 监督管理局（以下简称"国家药监局"）核准签发的苓桂术甘汤颗粒《药品注册证书》， 现将相关情况公告如下： 一、药品注册证书的主要内容 药品名称：苓桂术甘汤颗粒 审批结论：根据《中华人民共和国药品管理法》，经审查，本品符合药品注册的有关 要求，批准本品上市，发给药品注册证书。 二、该药品研发情况 苓桂术甘汤颗粒来源于汉代张仲景《金匮要略》，具有温阳化饮、健脾利湿功效，主 治中阳不足之痰饮。症见胸胁支满，目眩心悸，短气而咳，舌苔白滑，脉弦滑。处方由茯 苓、桂枝、白术、甘草组成 ...

人民财讯9月3日电，康恩贝（600572）9月3日晚间公告，公司近日收到国家药监局核准签发的苓桂术甘 汤颗粒《药品注册证书》。苓桂术甘汤颗粒来源于汉代张仲景《金匮要略》，具有温阳化饮、健脾利湿 功效，主治中阳不足之痰饮。 ...

Core Viewpoint - The company Kangnibei (600572.SH) has received approval from the National Medical Products Administration for the registration certificate of Linggui Zhugan Decoction Granules, indicating a significant advancement in its product offerings [1] Group 1: Product Information - Linggui Zhugan Decoction Granules are derived from Zhang Zhongjing's "Jinkui Yaolue" from the Han Dynasty, known for its warming, diuretic, and spleen-strengthening effects [1] - The decoction is indicated for conditions related to insufficient middle yang and phlegm retention, with symptoms including fullness in the chest and flanks, dizziness, palpitations, shortness of breath, cough, white and slippery tongue coating, and wiry and slippery pulse [1] - The formula consists of four key ingredients: Poria, Cinnamon Twig, Atractylodes, and Licorice [1]

中证报中证网讯（王珞）8月27日晚，康恩贝（600572）发布2025年半年度业绩报告。报告期内公司实 现营业收入33.58亿元，归母净利润3.54亿元；经营性现金流净额达4亿元，同比增长31%；销售费用率 和资产负债率均实现同比下降，整体经营质量得到提升。 公司坚持"中药大健康"核心战略，持续优化"一体两翼"业务布局。上半年，全品类中药业务收入保持稳 定，中药材与中药饮片板块实现收入5.83亿元，同比增长4.6%；特色健康消费品业务收入3.21亿元，同 比增长超过10%，显示出良好的增长韧性。 大品牌产品表现稳健，实现销售收入20.06亿元，同比有所增长。其中"康恩贝"肠炎宁系列通过多元营 销及渠道协同，销售收入突破5亿元，同比增长超15%；健康食品业务整体增长超10%，其中蛋白粉系 列销售收入过亿元、同比增长近30%；"金康灵力""金前列康"等品种销售增速均超20%，新推出的"康恩 贝"益生菌冻干粉也快速放量，形成新的增长点。 研发方面，公司上半年获中药改良型新药清喉咽含片批件1项、仿制药批件5项，恩替卡韦片和乙酰半胱 氨酸溶液获美国FDA批准上市。新立项研发项目74项，并通过剂型改良和循证研究持续提升核 ...

近日，康恩贝发布2025年半年报。披露公司上半年营收下滑2.61%至33.58亿元，归属净利减少7.48%至3.54亿元。主要系呼吸系统和抗感染产品因整体市场需求下降相应销售下降所致。 报告期内，公司大品牌大品种系列产品实现收入20.06亿元，同比增长0.5%。其中，"康恩贝"肠炎宁通过开展"旅行带上肠炎宁"及"5.29肠道健康日"联合KOL直播等系列营销活动，借助渠道端 "康恩贝"健康食品在稳存量基础上，通过加快新品类拓展、新渠道布局，上半年销售收入超3.5亿元，同比增长超10%，其中"康恩贝"蛋白粉系列销售收入过亿，同比增长近30%。 此外，公司重点培育品种"金康灵力"氢溴酸加兰他敏片销售增速超40%，"金前列康"黄莪胶囊销售增速近20%，及新上市产品"康恩贝"益生菌冻干粉增长较快，均已形成一定市场规模。 ...

Proton Pump Inhibitor (PPI) Industry Overview - Proton pump inhibitors (PPIs) are the most potent acid-suppressing medications, widely used for treating acid-related diseases such as peptic ulcers and gastroesophageal reflux disease [1][2] - The Chinese oral PPI market has maintained a scale of over 10 billion yuan from 2018 to 2024, with strong market demand [1][6] - The market has shown volatility due to the implementation of volume-based procurement plans for several generic PPIs, leading to price declines despite increasing sales [1][6] Market Size and Trends - The market size for oral PPIs in China is projected to decline by 10.5% year-on-year in 2024, influenced by price reductions from collective procurement [1][6] - The market for PPIs used for peptic ulcers is valued at 4.8 billion yuan, while the market for those used for gastroesophageal reflux disease is valued at 1.8 billion yuan [6] Product Landscape - As of the end of 2024, there are seven PPI products approved for sale in China, with major products including Rabeprazole, Aplrazole, Esomeprazole, and Omeprazole, collectively holding over 87% market share [1][8] - Rabeprazole leads the market with a share of 27.6%, followed by Aplrazole at 23.7% [1][8] Competitive Landscape - The PPI industry is characterized by intense competition, with numerous companies involved in the production of various PPI products [1][9] - As of July 2025, there are 134 products of Lansoprazole, 106 products of Pantoprazole, and 440 products of Omeprazole produced by over 180 companies in China [1][9] - The leading company for Rabeprazole is Jichuan Pharmaceutical, holding over 30% market share, while AstraZeneca leads the Omeprazole market with a 17.8% share [1][9]

（记者 王瀚黎） 每经AI快讯，康恩贝8月28日发布公告称，公司第十一届第十次董事会会议于2025年8月26日在杭州市 滨江区滨康路568号康恩贝中心22楼会议室召开。会议审议了《关于公司董事会聘任的经理层成员2024 年度业绩考核结果及年薪清算结果的议案》等文件。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ ...

Core Viewpoint - The National Medical Products Administration (NMPA) announced that 28 batches of drugs produced by 17 companies do not meet regulatory standards, highlighting quality control issues in the pharmaceutical industry [1][2][3]. Summary by Categories Non-compliance Details - Five batches of fusidic acid cream produced by Aumei Pharmaceutical are non-compliant due to particle size [1] - Two batches of loratadine syrup from Wante Pharmaceutical (Hainan) are non-compliant due to related substances [1] - One batch of sodium phosphate oral solution from Shanghai Haihong Industrial Group is non-compliant due to relative density [1] - Two batches of tosylate capsules from Shaanxi Xiyue Pharmaceutical are non-compliant due to dissolution rate [1] - One batch of acetylcysteine effervescent tablets from Zhejiang Jinhua Kang'enbei Biopharmaceutical is non-compliant due to physical properties [1] - Two batches of Twenty-five Flavor Coral Pills from Tibet Shenhou Pharmaceutical are non-compliant due to weight differences [1] Additional Non-compliance Findings - Two batches of Qili Powder from Hubei Minkan Pharmaceutical are non-compliant due to content measurement [2] - Four batches of Qingqi Huatan Pills from Hubei Ruihua Pharmaceutical are non-compliant due to dosage discrepancies [2] - Two batches of red peony from Sichuan Jinke Pharmaceutical and Sichuan Yixiangkang Pharmaceutical are non-compliant due to physical properties [2] - Three batches of red ginseng (red ginseng slices) from multiple companies are non-compliant due to identification issues and pesticide residue [2] - One batch of Gentian from Jiangsu Heshengtang Pharmaceutical is non-compliant due to impurities [2] - One batch of wild chrysanthemum from Jiangxi Xinjian Pharmaceutical is non-compliant due to content measurement [2] Regulatory Actions - The NMPA has mandated that the involved companies take risk control measures such as halting sales and conducting recalls [3] - Investigations into the causes of non-compliance are required, along with corrective actions [3] - Provincial drug supervision departments are instructed to investigate potential illegal activities by the companies involved [3] Public Awareness Initiatives - The NMPA has provided educational information regarding the significance of various non-compliance indicators, such as particle size, related substances, relative density, dissolution rate, physical properties, weight differences, content measurement, identification, pesticide residues, total reducing sugars, impurities, and moisture content [4][5]

（文章来源：证券日报） 证券日报网讯 8月27日晚间，康恩贝发布公告称，公司第十一届董事会第十次会议审议通过了《关于公 司董事会聘任的经理层成员2024年度业绩考核结果及年薪清算结果的议案》等多项议案。 ...